464 related articles for article (PubMed ID: 26506419)
1. Active glycolytic metabolism in CD133(+) hepatocellular cancer stem cells: regulation by MIR-122.
Song K; Kwon H; Han C; Zhang J; Dash S; Lim K; Wu T
Oncotarget; 2015 Dec; 6(38):40822-35. PubMed ID: 26506419
[TBL] [Abstract][Full Text] [Related]
2. microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb.
Zhang J; Luo N; Luo Y; Peng Z; Zhang T; Li S
Int J Oncol; 2012 Mar; 40(3):747-56. PubMed ID: 22025269
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effects of transcription factor Ikaros on the expression of liver cancer stem cell marker CD133 in hepatocellular carcinoma.
Zhang L; Li H; Ge C; Li M; Zhao FY; Hou HL; Zhu MX; Tian H; Zhang LX; Chen TY; Jiang GP; Xie HY; Cui Y; Yao M; Li JJ
Oncotarget; 2014 Nov; 5(21):10621-35. PubMed ID: 25301737
[TBL] [Abstract][Full Text] [Related]
4. Transient mTOR inhibition facilitates continuous growth of liver tumors by modulating the maintenance of CD133+ cell populations.
Yang Z; Zhang L; Ma A; Liu L; Li J; Gu J; Liu Y
PLoS One; 2011; 6(12):e28405. PubMed ID: 22145042
[TBL] [Abstract][Full Text] [Related]
5. Isolation and characterization of hepatic cancer cells with stem-like properties from hepatocellular carcinoma.
Tomuleasa C; Soritau O; Rus-Ciuca D; Pop T; Todea D; Mosteanu O; Pintea B; Foris V; Susman S; Kacsó G; Irimie A
J Gastrointestin Liver Dis; 2010 Mar; 19(1):61-7. PubMed ID: 20361077
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA profiling of a CD133(+) spheroid-forming subpopulation of the OVCAR3 human ovarian cancer cell line.
Nam EJ; Lee M; Yim GW; Kim JH; Kim S; Kim SW; Kim YT
BMC Med Genomics; 2012 May; 5():18. PubMed ID: 22643117
[TBL] [Abstract][Full Text] [Related]
7. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1.
Ma S; Tang KH; Chan YP; Lee TK; Kwan PS; Castilho A; Ng I; Man K; Wong N; To KF; Zheng BJ; Lai PB; Lo CM; Chan KW; Guan XY
Cell Stem Cell; 2010 Dec; 7(6):694-707. PubMed ID: 21112564
[TBL] [Abstract][Full Text] [Related]
8. Arsenite inhibits the function of CD133
Tang H; Jin Y; Jin S; Tan Z; Peng Z; Kuang Y
Tumour Biol; 2016 Oct; 37(10):14103-14115. PubMed ID: 27517564
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the cancer stem cells-like properties by arsenic trioxide, involved in the attenuation of endogenous transforming growth factor beta signal.
Li Y; Jiang F; Liu Q; Shen J; Wang X; Li Z; Zhang J; Lu X
Toxicol Sci; 2015 Jan; 143(1):156-64. PubMed ID: 25304214
[TBL] [Abstract][Full Text] [Related]
10. ELK3 promotes the migration and invasion of liver cancer stem cells by targeting HIF-1α.
Lee JH; Hur W; Hong SW; Kim JH; Kim SM; Lee EB; Yoon SK
Oncol Rep; 2017 Feb; 37(2):813-822. PubMed ID: 27959451
[TBL] [Abstract][Full Text] [Related]
11. Elevated expression of the stem cell marker CD133 associated with Line-1 demethylation in hepatocellular carcinoma.
Zhang C; Xu Y; Zhao J; Fan L; Jiang G; Li R; Ling Y; Wu M; Wei L
Ann Surg Oncol; 2011 Aug; 18(8):2373-80. PubMed ID: 21331808
[TBL] [Abstract][Full Text] [Related]
12. Description of the CD133+ subpopulation of the human ovarian cancer cell line OVCAR3.
Guo R; Wu Q; Liu F; Wang Y
Oncol Rep; 2011 Jan; 25(1):141-6. PubMed ID: 21109969
[TBL] [Abstract][Full Text] [Related]
13. Regulatory role of miR-142-3p on the functional hepatic cancer stem cell marker CD133.
Chai S; Tong M; Ng KY; Kwan PS; Chan YP; Fung TM; Lee TK; Wong N; Xie D; Yuan YF; Guan XY; Ma S
Oncotarget; 2014 Jul; 5(14):5725-35. PubMed ID: 25015418
[TBL] [Abstract][Full Text] [Related]
14. CD133 silencing inhibits stemness properties and enhances chemoradiosensitivity in CD133-positive liver cancer stem cells.
Lan X; Wu YZ; Wang Y; Wu FR; Zang CB; Tang C; Cao S; Li SL
Int J Mol Med; 2013 Feb; 31(2):315-24. PubMed ID: 23233126
[TBL] [Abstract][Full Text] [Related]
15. Biology and clinical implications of CD133(+) liver cancer stem cells.
Ma S
Exp Cell Res; 2013 Jan; 319(2):126-32. PubMed ID: 22999864
[TBL] [Abstract][Full Text] [Related]
16. An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma.
Li M; Zhang L; Ge C; Chen L; Fang T; Li H; Tian H; Liu J; Chen T; Jiang G; Xie H; Cui Y; Yao M; Li J
Oncotarget; 2015 Sep; 6(28):25149-60. PubMed ID: 26327240
[TBL] [Abstract][Full Text] [Related]
17. Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations.
Ma S; Chan KW; Lee TK; Tang KH; Wo JY; Zheng BJ; Guan XY
Mol Cancer Res; 2008 Jul; 6(7):1146-53. PubMed ID: 18644979
[TBL] [Abstract][Full Text] [Related]
18. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
Le H; Zeng F; Xu L; Liu X; Huang Y
Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862
[TBL] [Abstract][Full Text] [Related]
19. Plastic induction of CD133AC133-positive cells in the microenvironment of glioblastoma spheroids.
Ohnishi K; Tani T; Bando S; Kubota N; Fujii Y; Hatano O; Harada H
Int J Oncol; 2014 Aug; 45(2):581-6. PubMed ID: 24897999
[TBL] [Abstract][Full Text] [Related]
20. Hexokinase II in CD133+ and CD133- hepatoma BEL-7402 Cells.
Gong L; Cui Z; Yu X; Wei Y; Peng J; Leng X
Pathol Oncol Res; 2012 Apr; 18(2):377-81. PubMed ID: 21909686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]